SNV 3
Alternative Names: SNV-3Latest Information Update: 14 Jan 2022
At a glance
- Originator Calidi Biotherapeutics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 03 Jan 2022 Early research in Solid tumours in USA (IV) before January 2022 (Calidi Biotherapeutics pipeline, January 2022)